Up to Twelve-Month Efficacy Against Influenza Observed; Good Protection Demonstrated in Trial Evaluating the Benefit of the Recommended Two Doses
for Previously Unvaccinated Children
HONOLULU, May 5 /PRNewswire/ -- Data from two new studies presented at the annual meeting of the Pediatric Academic Societies (PAS) demonstrate that FluMist(R) (Influenza Virus Vaccine Live, Intranasal) may offer children both durable protection against influenza, as well as significant protection for previously unvaccinated children who receive the recommended two-dose regimen approximately four weeks apart. In the efficacy trial evaluating one and two doses in previously unvaccinated children, protection was also observed among previously unvaccinated children who received only one dose of FluMist.
"These data add to the growing body of evidence that FluMist offers good protection against influenza for children eligible to receive it," commented Chris Ambrose, M.D., director, medical affairs. "We hope that this data will help support public health efforts to encourage parents to vaccinate their children each year as soon as vaccine is available and follow dosing recommendations to optimally protect children against this infectious disease."
FluMist is different from the flu shot in that it uses live, attenuated -- or weakened -- viruses within the vaccine to help stimulate an immune response that is designed to closely resemble the body's natural response to an influenza infection.
Efficacy of FluMist Among Previously Unvaccinated Children
In a study involving 3,200 previously unvaccinated children between the
ages of six (1) and 36 months, the efficacy of one dose of FluMist was
compared to the recommended two doses. The study showed that for children
receiving one dose of Fl
Copyright©2008 PR Newswire.
All rights reserved